Eloqua Limited (ELOQ)
Based in Vienna, VA, Eloqua Limited scheduled an $84 million IPO with a market capitalization of $336 at a price range mid-point of $10.50 for Thursday, August 2, 2012.
ELOQ is a cloud company that provides on-demand Revenue Performance Management software solutions that are designed to enable businesses to accelerate revenue growth and improve revenue predictability.
For the six months ended June 2012 quarter revenue increased 42% to $45 million from $32 million. On a comparable basis ELOQ’s loss dropped to -$6 million from -$4 million.
Pre-IPO ELOQ has a shareholder deficit of $-9 million on a pro forma basis. As of June 30, 2012, ELOG had an accumulated deficit of $190.5 million.
Globus Medical (GMED)
Based in Audubon, PA, Globus Medical (GMED) scheduled a $200 million IPO with a market capitalization of $1.55 billion at a price range mid-point of $17, for Thursday, April 2, 2012.
GMED is a medical device company focused exclusively on the design, development and commercialization of products that promote healing in patients with spine disorders.
Founded in 2003, GMED revenue for the March 2012 quarter was $95 million, up 22% from the year earlier quarter. Net income increased 23% to $18 million from $14 million. 75% of the IPO is from selling shareholders.
Based in Glendale, CA, LegalZoom.com scheduled an $88 million IPO with a market capitalization of $443 million at a price range mid-point of $11 for Friday, August 3, 2012.
LegalZoom is the leading online provider of services that meet the legal needs of small businesses and consumers in the United States.
March 2012 quarter’s sales increased 24% to $47 million from $38 million, compared to the year earlier quarter, and loss improved to -$.1 million from -$1 million.
In the March 2012 quarter EBITDA was 4% of revenue. 2011 profit was inflated by a $6 million tax refund.
Stemline Therapeutics (STML)
Based in New York, NY, Stemline Therapeutics (STML) scheduled a $42 million IPO with a market capitalization of $128 million at a price range mid-point of $12 for Wednesday, August 1, 2012.
STML is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.
As of July 19, 2012 STML had eight full-time employees. The chairman, CEO and president owns 52% pre-IPO. STML’s pro forma net worth pre-IPO is $483,000 and the company has an accumulated deficit of $7.2 million, so it is small compared with other clinical stage biopharma IPOs.